Definitive Contract 75F40120C00036

Nanopharm LIMITED was awarded a definitive cost-no-fee contract valued at one hundred twenty-nine thousand four hundred sixty-nine dollars by the Department of Health and Human Services Food and Drug Administration to support the agency's PMQWP 202 broad agency announcement. Under the contract, Nanopharm will perform work investigating orthogonal analytical approaches to demonstrate bioequivalence of nasal suspension formulations. The place of performance will be Silver Spring, Maryland. No set-aside designation was used for this award to the for-profit limited liability company.